NEW YORK, Oct. 5, 2016 /PRNewswire/ -- Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on
behalf of purchasers of the securities of Trinity Biotech plc
("Trinity" or the "Company") (NASDAQ: TRIB). Such investors are
advised to contact Peretz Bronstein
or his investor relations analyst Yael
Hurwitz at info@bgandg.com or 212-697-6484.
The investigation concerns whether Trinity and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On October 4, 2016, pre-market,
Trinity revealed that it was withdrawing its 510(k) premarket
notification submission for the Meritas Troponin-I Test and Meritas
Point-of-Care Analyzer, following the U.S. Food and Drug
Administration's advice. Trinity also said it would decrease its
spending by roughly 85%, to $1.5
million from $9 million each
year, and that it would close its Swedish facility, eliminating 40
jobs. Following this news, Trinity stock dropped $6.53 per share, or 50.27%, to close at
$6.46 on October 4, 2016.
If you are aware of any facts relating to this investigation, or
purchased shares of Trinity, you can assist this investigation by
visiting the firm's site: http://www.bgandg.com/trib. You can also
contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-trinity-biotech-plc-trib-300339865.html
SOURCE Bronstein, Gewirtz & Grossman, LLC